Letter to the editor  Anna Coutsoudis and colleagues worry that international organisations have too hastily endorsed a strategy to provide lifelong triple antiretroviral therapy (ART), irrespective of CD4 count, to pregnant women with HIV in high-burden countries. This strategy for preventing mother-to-child transmission is called Option B+. It was pioneered in Malawi, where the lack of CD4 testing resources impeded effective rollout of WHO Options A or B. Without timely CD4 results, both WHO regimens risk withholding therapy from women who need it. Other countries share this limitation. Yet even where all three regimens are feasible, Option B+ might be best.

Source URL: http://www.msh.org/resources/is-option-b-the-best-choice

Links: